REACH provides the opportunity to advance public health and environmental protection and to boost public confidence in the use of chemicals. Not surprisingly at this stage there are many uncertainties on the details of its implementation. From a risk assessor's viewpoint relevant issues are:
REACH is very wide in its scope. It represents an important legislative development towards achieving the European Communities' objective of attaining a high level of public health and environmental protection throughout its Member States. It also provides a particular opportunity to improve the confidence of the public about the safety of all chemicals manufactured in quantities over 10 tonnes. For the first time, these chemicals will be subject to risk assessment procedures (termed chemical safety reports). For chemicals where the risk assessment indicates a significant risk, it is intended that the use of the chemical will be restricted or banned, provided there is an adequate substitute (REACH, 2006) .
As with all such major legislative changes in the EU, REACH represents a compromise between the different objectives of the various stakeholders.
Inevitably, the chemical industry tends to view REACH as a major economic burden that will limit its competitiveness globally. On the other hand, some specialists may consider that it provides an insufficient level of protection of public health and environmental safety. Meanwhile, animal rights groups remain concerned about the number of additional animals that will be required for testing purposes. At the present time there are, not surprisingly, many uncertainties about how REACH will work out in practice and what are the full implications of the compromises that have been made.
The novelty of REACH is its very large scale. It appears unlikely that any particularly innovative scientific practices will be required in the initial stages of REACH implementation. Nonetheless, these practices have the potential to be developed at a later stage. The major early challenges in implementing REACH are expected to be organisational ones, for example: efficient and reliable information management; effective communication with the many stakeholders; setting up and managing a new and independent organisation (The European Chemicals Agency). The timescale is very short, bearing in mind the enormity of the task and the absence of existing personnel and the temptation of adopting a ''checklist'' approach to the authorisation of individual chemicals.
From the point of view of one group of stakeholders (who have been peripheral to the REACH debate so far), namely the risk assessors, the following issues require further consideration:
identification of data requirements and priorities for assessment; conduct of the risk assessment process; harmonisation of risk assessment procedures; balancing risks and benefits; ensuring the supply of suitable experts; developing a readily utilisable database and provision of guidelines.
Each of the above issues is considered below in more detail.
(a) Identification of data requirements and priorities for assessment
The first step in assessing the risk to humans and to the environment from chemicals is to identify exposure. As proposed in REACH, exposure is initially identified on the basis of tonnage manufactured. This is, without doubt, a very convenient framework for administrative purposes. It must be recognised, however, that manufactured tonnage is a very poor surrogate for the number of the population exposed, the level of exposure of humans, and the environment and the hazards involved. It is therefore crucial that procedures are put in place from the outset for the identification of chemicals that merit a more detailed assessment.
For this purpose, the following are among the criteria that should be considered. It is noted that some of these have already been recognised in the REACH proposals, although how they will be considered is less clear:
Structural features that indicate a likelihood of mutagenic, carcinogenic, reproductive (CMR) and/or sensitising effects and/ or of persistence in the body and/or in the environment (PBT/vPvB). Chemicals for which there is an estimate of high exposure despite the low tonnage manufactured. This is particularly important if J significant exposure of vulnerable groups of the population is likely (e.g., young children) and J there are sources of significant exposure to the chemical not covered by REACH (e.g., in food, cosmetics). Exposure to closely related chemicals that are known or are likely to have rather similar hazard properties. In such circumstances, the total tonnage of the group of chemicals should be considered in the risk assessment; Substances for which exposure is likely to be in the form of nanoparticles. There are many reasons for anticipating a major growth of products involving nanomaterials. The use of tonnage considerations alone is clearly not appropriate for substances that can exist in the form of free nanoparticles. In many cases, the nanomaterial will be derived from an existing chemical. This leads to the question: Do such nanomaterials require a separate risk assessment from other forms of the existing chemical? A rational science-based decision procedure is needed to address this (SCENIHR, 2006) .
It is also essential to the credibility of the process that each risk assessment consider all the relevant available data on the chemical (including the published data), not simply the minimum information required by REACH.
(b) The conduct of the risk assessment process
At the heart of the REACH process are the risk assessments on individual chemicals. Many thousands of risk assessments (chemical safety reports) are envisaged, some rather brief, while others will involve considerable detail. A risk assessment should be an objective, high quality process based on the best current scientific understanding available. It should be free from the influence of risk managers and other stakeholders. The use of the findings of each risk assessment, however, is rightly the responsibility of the risk managers and many other stakeholders.
Before the mid-1990s, risk assessment advice to the Commission Services was provided by committees comprising representatives/nominees of Member States. Following the BSE crisis, the system was restructured (EU, 1997) and the onus for risk assessment advice was handed to committees of scientists. They are not influenced by the country in which they are based or the organisation that employs them. The Commission's reasons for the change were to ensure a high quality, fully independent and transparent procedure likely to attain the trust of the various stakeholders. Almost a decade of experience with the new system has demonstrated that a number of substantial improvements have been achieved.
In respect of existing chemicals, the final overview of the risk assessment has been carried out by the Scientific Committee on Health and Environmental Risk (SCHER, 2006) and its predecessor, the Scientific Committee on Toxicity, Ecotoxicity and the Environment, over the past 10 years (CSTEE, 2002) . The value of their input into the assessment process for existing chemicals is widely accepted.
As currently proposed under REACH, the manufacturer (or an organisation acting on behalf of the manufacturer) will be responsible for the risk assessment of each chemical. While it is reasonable to expect those who produce the chemicals to provide an assessment of their safety, it is inevitable that this will result in very variable standards between individual risk assessments. A proper review of these risk assessments is, therefore, imperative from the perspective of ensuring both safety and even-handedness in dealing with different manufacturers. This cannot simply be a checklist approach.
It is planned that the risk assessments will be overseen by a scientific committee comprising representatives of each of the Member States. No independent scientific examination of the individual risk assessments is envisaged. This reversion to a system that was deemed to have failed in the 1990s is highly regrettable. It is noted that when the European Food Safety Authority (EFSA) was set up in 2002 (also faced with a major requirement for risk assessments on individual substances), it further developed the role of the independent scientific committees (panels) (EFSA, 2002). EFSA's risk assessment procedures have proved to be both effective and acceptable to stakeholders.
Mechanisms need to be introduced into REACH for the independent evaluation of the overall risk assessment process along with an auditing of particular risk assessments carried out for the new European Chemicals Agency (ECA).
A mechanism should also be put into place to re-examine chemicals within an agreed time frame where there is wide exposure of humans and/or the environment and a high degree of uncertainty in the initial risk assessment.
(c) Harmonisation of risk assessment procedures
The scientists who are very experienced in risk assessment have an important role in establishing a sound framework in each of the areas identified above. They must ensure that the risk assessment process continues to evolve in the light of new scientific understanding. It is also important that procedures are harmonised, wherever practicable, to ensure transparency and to facilitate the ready transfer of information and assessments between particular domains of chemical use (SSC, 2003) .
Risk assessment of existing chemicals in the EU to date has focused on those chemicals where there is a relatively large amount of information. However, even for such chemicals there are gaps in the data, which may delay completion of the risk assessment. In the case of REACH, the data requirements for all but the highest tonnage chemicals are quite limited. The emphasis on scientific judgement will, therefore, be greater than for those chemicals evaluated to date. There are rather optimistic assumptions in the REACH proposals about the reliability of both QSAR and in vitro testing as a means of compensating for missing data. In both cases, substantial scientific research is still required to fulfil their intended role (REACH, 2006) . To achieve the objectives (in addition to the need discussed below to ensure that there are sufficient experts available of appropriate expertise to carry out the risk assessments), the tools used need to be clearly described and additional tools developed. It is beyond the scope of this epilogue to address these issues in detail. For a fuller discussion, the reports of the Scientific Steering Committee (SSC 2000 (SSC , 2003 may be consulted.
A standardisation of the terminology, which should include words used to describe levels of risk. It is also necessary to ensure that the terms selected are appropriate for translation across the languages of the many Member States. Improvement of methods for estimating total exposure to individual chemicals and groups of chemicals. Development of procedures that utilise all the available data. These should include the potential for using findings from studies used for assessing human risk for ecotoxicological risk assessment and vice versa (Bridges and Bridges, 2004) . A more formalised and transparent procedure for weighting the evidence and for the expression of uncertainties in the risk assessment in order that the basis is properly defined for the judgements that are made in each risk assessment procedure. A concerted effort to develop and utilise appropriate nonanimal tests for risk assessment purposes.
These harmonisation issues have been raised in several reports from the EU scientific committees over the past decade. An important development in this respect in the past 2 years has been an annual meeting of all of the chairs of EU independent advisory committees concerned with human health and environmental issues at which harmonisation issues are discussed. The development of the risk assessment practices under REACH should incorporate this harmonised best risk assessment practice.
(d) Balancing risks and benefits
An important and potentially innovative element of REACH is the proposal for two parallel committees, the one discussed above, which is concerned with risk assessment, and the socioeconomic committee, which will address other facets of the use and possible restrictions on the use of specific chemicals. Over the past 20-30 years, the citizens of Western Europe have become increasingly risk averse. A transparent and objective process for identifying the benefits of chemicals (and other stressors and processes) is urgently needed to ensure that the economic prosperity of the European Community continues to increase, without significant adverse consequences to either human health or the environment. The introduction in the ECA of a socioeconomic committee provides an excellent opportunity to initiate a risk benefit approach. It is vital, however, that it is not simply seen as a means of overruling concerns about the risks of individual chemicals. Inevitably, there are questions to which answers cannot be found at this stage. For example, will sustainability be used as a criterion in determining the overall acceptability of particular chemicals/chemical classes and, if so, how will this be assessed?
(e) Ensuring the supply of suitable experts
The demand for risk assessments in the EU has grown substantially in the past few years, and even without the introduction of REACH, this growth would have continued. The implementation of REACH will inevitably require an input from experts in testing procedures and risk assessors. There appears to be little discussion at the higher levels in the Commission on where this expertise will come from. It is unfortunately the case that as the demand for risk assessment has increased, the availability of appropriately trained experts has decreased and, moreover, the total number of suitable training courses across the Member States has diminished (SSC, 2000) .
The implication of reducing the data requirements for accreditation under REACH, compared with that originally envisaged, is that a much higher degree of judgement is demanded of the risk assessors. This inevitably requires a high level of training and of experience. A concerted action by stakeholders is needed to ensure that the necessary training is put into place promptly.
(f) Developing a readily utilisable database
The present databases on chemicals and their hazardous properties are rather limited and access to them is very restricted. REACH will garner risk assessments on many thousands of chemicals. It is essential that this information is used to develop an appropriate database, hopefully one that is compatible with other relevant databases in the EU. In devising the most appropriate format for such a database, its potential uses must be considered. These include the following: identification of structure activity relationships for both toxicity in humans and for ecotoxicological effects to enable the evolution of more informed and trusted ''read across'' procedures; more reliable estimation of current human and environmental exposure to particular chemicals and to particular classes of chemicals; a sounder rationale for determining priorities for risk assessments and an invaluable reference point from which to develop new non-animal tests, thereby enabling a further reduction in animal use for testing purposes; the informed design of safer, novel chemicals.
To attain these objectives, the database will need to be well resourced and continually updated. It should include assumptions made in each risk assessment. Access to the database by those with a legitimate interest is also very important. Means will have to be found to overcome the confidentiality issues that have bedevilled progress in toxicology for many years.
(g) Provision of guidelines
To ensure transparency and trust and to facilitate efficiency, guidelines should be provided at an early stage that indicate how major issues will be addressed. Priorities for such guidelines include the following: (i) Substitution is an important element in the original REACH proposal. The rationale for favouring substitution of one chemical by another needs to be properly defined. This will need to incorporate issues such as the balancing of human and environmental risks and benefits. (ii) Characterising the benefits of REACH. It is important to identify measurable parameters for evaluating the benefits of REACH to both human and environmental health and as a stimulant to important novel product development.
Concluding remarks
The implementation of REACH will require a massive increase in the demand for risk assessments within the EU. It is crucial that this does not result in such a fall in the quality of the risk assessment that the findings of the risk assessments, conducted for other purposes within the EU, is undermined. A number of proposals are made here that would help to maintain the current, widely accepted standards and to assist the European Chemicals Agency in its very important mission.
